Status:
TERMINATED
Screening of Cancer Patients to Assess Impact of COVID-19
Lead Sponsor:
University Health Network, Toronto
Conditions:
Covid-19
Cancer
Eligibility:
All Genders
Brief Summary
The purpose of this study is to investigate the impact of COVID -19 in the cancer patient population. This will be done by looking at the rate of asymptomatic COVID-19 infection in cancer patients rec...
Detailed Description
Given increasing community transmission and the possibility of asymptomatic carriage of virus, it is important to study whether asymptomatic shedders of virus are playing a role in propagating the pan...
Eligibility Criteria
Inclusion
- Patients having an active malignancy who are planned to start therapy within 6 weeks of consent or are receiving a treatment for active malignancy.
- The patient falls under either of the following categories:
- Asymptomatic for COVID-19 (as per daily screening at the hospital entrance).
- Has symptoms similar to those of COVID-19 (e.g. fever or flu-like symptoms such as cough or shortness of breath) that are assessed by the overseeing Investigator as being related to disease and unrelated to COVID-19 infection.
- Note: Patients who recovered from previous COVID-19 infection will be eligible.
- No contraindication to performing a NP swab and blood work.
Exclusion
- Any patients with fever, or flu-like symptoms assessed by the Investigator to be related or potentially related to COVID-19 infection will not be eligible.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 3-4
Key Trial Info
Start Date :
May 11 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 6 2022
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT04373005
Start Date
May 11 2020
End Date
October 6 2022
Last Update
December 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 1Z5